NCT00596830_2B | R Documentation |
Kaplan-Meier digitized data from NCT00596830, figure 2B (PMID 24888810). A reported sample size of 681 for a primary endpoint of OS in lung cancer.
NCT00596830_2B
A data frame of 681 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (control, figitumumab) | |
Langer CJ, Novello S, Park K, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014; 32: 2059–66.
summary(NCT00596830_2B)
kmplot(NCT00596830_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.